JP2013524775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013524775A5 JP2013524775A5 JP2012556223A JP2012556223A JP2013524775A5 JP 2013524775 A5 JP2013524775 A5 JP 2013524775A5 JP 2012556223 A JP2012556223 A JP 2012556223A JP 2012556223 A JP2012556223 A JP 2012556223A JP 2013524775 A5 JP2013524775 A5 JP 2013524775A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- recombinant
- protein
- sample
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 21
- 102000014150 Interferons Human genes 0.000 claims 20
- 108010050904 Interferons Proteins 0.000 claims 20
- 238000000605 extraction Methods 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 9
- 239000012134 supernatant fraction Substances 0.000 claims 7
- 108010005714 Interferon beta-1b Proteins 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 229960003161 interferon beta-1b Drugs 0.000 claims 6
- 108090000467 Interferon-beta Proteins 0.000 claims 4
- 102000003996 Interferon-beta Human genes 0.000 claims 4
- BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 claims 4
- 229960001388 interferon-beta Drugs 0.000 claims 4
- 102220519361 Coatomer subunit alpha_C17S_mutation Human genes 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000006228 supernatant Substances 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000003196 chaotropic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000000805 cytoplasm Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims 2
- HEGSGKPQLMEBJL-RQICVUQASA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octoxyoxane-3,4,5-triol Chemical compound CCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RQICVUQASA-N 0.000 claims 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims 1
- WKALLSVICJPZTM-UHFFFAOYSA-N 3-[decyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O WKALLSVICJPZTM-UHFFFAOYSA-N 0.000 claims 1
- QZRAABPTWGFNIU-UHFFFAOYSA-N 3-[dimethyl(octyl)azaniumyl]propane-1-sulfonate Chemical group CCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O QZRAABPTWGFNIU-UHFFFAOYSA-N 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 102100022469 Interferon kappa Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000120 cytopathologic effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 1
- 108010080375 interferon kappa Proteins 0.000 claims 1
- 108010045648 interferon omega 1 Proteins 0.000 claims 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 238000001525 receptor binding assay Methods 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31067110P | 2010-03-04 | 2010-03-04 | |
| US61/310,671 | 2010-03-04 | ||
| PCT/US2011/026921 WO2011109556A2 (en) | 2010-03-04 | 2011-03-02 | Method for producing soluble recombinant interferon protein without denaturing |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013524775A JP2013524775A (ja) | 2013-06-20 |
| JP2013524775A5 true JP2013524775A5 (enExample) | 2014-04-17 |
| JP5840148B2 JP5840148B2 (ja) | 2016-01-06 |
Family
ID=44531690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556223A Expired - Fee Related JP5840148B2 (ja) | 2010-03-04 | 2011-03-02 | 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9187543B2 (enExample) |
| EP (1) | EP2542574B1 (enExample) |
| JP (1) | JP5840148B2 (enExample) |
| KR (1) | KR101857825B1 (enExample) |
| CN (1) | CN102906108B (enExample) |
| AU (1) | AU2011223627B2 (enExample) |
| BR (1) | BR112012022292A2 (enExample) |
| CA (1) | CA2791361C (enExample) |
| CL (1) | CL2012002378A1 (enExample) |
| CO (1) | CO6592086A2 (enExample) |
| ES (1) | ES2639398T3 (enExample) |
| MX (1) | MX2012010148A (enExample) |
| NZ (1) | NZ602255A (enExample) |
| PE (1) | PE20130557A1 (enExample) |
| RU (1) | RU2573909C2 (enExample) |
| WO (1) | WO2011109556A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130557A1 (es) | 2010-03-04 | 2013-05-19 | Pfenex Inc | Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| CN104151420A (zh) * | 2013-05-15 | 2014-11-19 | 复旦大学 | 长效干扰素及其制备方法和用途 |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| CN107099569B (zh) * | 2017-06-30 | 2021-05-07 | 北京生物制品研究所有限责任公司 | 一种规模化发酵生产重组人干扰素β1b蛋白的方法 |
| CN116194460A (zh) * | 2020-06-09 | 2023-05-30 | Icosavax股份有限公司 | 制备病毒样颗粒的方法 |
| CN116120424A (zh) * | 2022-06-06 | 2023-05-16 | 江苏靶标生物医药研究所有限公司 | 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4755465A (en) * | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
| US5281532A (en) * | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
| US4695455A (en) * | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
| US4695462A (en) * | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
| GB8517071D0 (en) | 1985-07-05 | 1985-08-14 | Hoffmann La Roche | Gram-positive expression control sequence |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
| DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| NO176799C (no) | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
| JP2618618B2 (ja) | 1988-03-04 | 1997-06-11 | 協和醗酵工業株式会社 | 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体 |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5128130A (en) * | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
| US5055294A (en) * | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
| CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US6372206B1 (en) | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5169760A (en) * | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
| GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| AU8735991A (en) | 1990-09-28 | 1992-04-28 | Ortho Pharmaceutical Corporation | Hybrid growth factors |
| US5508192A (en) * | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5240834A (en) * | 1991-01-22 | 1993-08-31 | Albert Einstein College Of Medicine Of Yeshiva University | Solubilization of protein after bacterial expression using sarkosyl |
| DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
| US6171824B1 (en) | 1991-08-30 | 2001-01-09 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
| US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| ITFI940106A1 (it) | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| RU2098124C1 (ru) * | 1994-10-24 | 1997-12-10 | Общество с ограниченной ответственностью "Ниготек" | Способ получения интерферона |
| IT1285405B1 (it) | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
| US5814485A (en) | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
| DE69815707T2 (de) * | 1997-11-20 | 2004-07-01 | Vical, Inc., San Diego | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
| WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
| US20030167531A1 (en) * | 1998-07-10 | 2003-09-04 | Russell Douglas A. | Expression and purification of bioactive, authentic polypeptides from plants |
| WO2000049146A1 (en) | 1999-02-18 | 2000-08-24 | Rmf Dictagene S.A. | Malaria vaccine |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| KR100358948B1 (ko) * | 2000-03-31 | 2002-10-31 | 한국과학기술원 | 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균 |
| JP4799803B2 (ja) | 2000-09-08 | 2011-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | Ｇ−ｃｓｆアナログ組成物および方法 |
| PL209928B1 (pl) * | 2000-11-07 | 2011-11-30 | Novartis Vaccines & Diagnostic | Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β |
| RU2003125641A (ru) | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный колониестимулирующий гранулоцитарный фактор (g-csf) с уменьшенной иммуногенностью |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| EP1366455B1 (en) | 2001-02-19 | 2008-07-02 | MERCK PATENT GmbH | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
| IL159524A0 (en) | 2001-07-11 | 2004-06-01 | Maxygen Holdings Ltd | G-csf conjugates |
| WO2003023050A2 (en) * | 2001-09-10 | 2003-03-20 | Emd Biosciences, Inc. | Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first |
| US20040247562A1 (en) | 2001-09-28 | 2004-12-09 | Sang Yup Lee | Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3 |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| SI21273A (sl) * | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| AU2003267827A1 (en) | 2002-08-31 | 2004-03-19 | Cj Corp. | Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform |
| US9453251B2 (en) * | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| US8399217B2 (en) * | 2003-03-14 | 2013-03-19 | Brookhaven Science Associates, Llc | High density growth of T7 expression strains with auto-induction option |
| JP5087741B2 (ja) | 2003-11-19 | 2012-12-05 | フェネックス インコーポレイテッド | 改良タンパク質発現系 |
| AU2004317306B2 (en) * | 2003-11-21 | 2010-09-02 | Pelican Technology Holdings, Inc. | Improved expression systems with Sec-system secretion |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| AU2005206951B2 (en) | 2004-01-16 | 2010-08-19 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP2008507294A (ja) * | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
| CA2591235C (en) * | 2004-12-20 | 2014-03-11 | Cadila Healthcare Limited | Process for preparing high levels of interferon beta |
| WO2006067170A1 (en) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
| GB0605684D0 (en) | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
| WO2007142954A2 (en) * | 2006-05-30 | 2007-12-13 | Dow Global Technologies Inc. | Codon optimization method |
| EP1939212A1 (en) * | 2006-12-20 | 2008-07-02 | LEK Pharmaceuticals D.D. | Organic compounds |
| EP2468869B1 (en) * | 2007-01-31 | 2015-03-18 | Pfenex Inc. | Bacterial leader sequences for increased expression |
| EP2615172A1 (en) | 2007-04-27 | 2013-07-17 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) * | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| BRPI0815416A2 (pt) * | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| EP3660032B1 (en) | 2009-06-25 | 2025-10-22 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| PE20130557A1 (es) | 2010-03-04 | 2013-05-19 | Pfenex Inc | Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion |
| EP2552949B1 (en) * | 2010-04-01 | 2016-08-17 | Pfenex Inc. | Methods for g-csf production in a pseudomonas host cell |
-
2011
- 2011-03-02 PE PE2012001389A patent/PE20130557A1/es not_active Application Discontinuation
- 2011-03-02 NZ NZ602255A patent/NZ602255A/en not_active IP Right Cessation
- 2011-03-02 MX MX2012010148A patent/MX2012010148A/es unknown
- 2011-03-02 WO PCT/US2011/026921 patent/WO2011109556A2/en not_active Ceased
- 2011-03-02 CA CA2791361A patent/CA2791361C/en not_active Expired - Fee Related
- 2011-03-02 ES ES11751317.6T patent/ES2639398T3/es active Active
- 2011-03-02 KR KR1020127025760A patent/KR101857825B1/ko not_active Expired - Fee Related
- 2011-03-02 EP EP11751317.6A patent/EP2542574B1/en not_active Not-in-force
- 2011-03-02 BR BR112012022292A patent/BR112012022292A2/pt not_active IP Right Cessation
- 2011-03-02 US US13/039,183 patent/US9187543B2/en not_active Expired - Fee Related
- 2011-03-02 AU AU2011223627A patent/AU2011223627B2/en not_active Ceased
- 2011-03-02 CN CN201180021026.9A patent/CN102906108B/zh not_active Expired - Fee Related
- 2011-03-02 RU RU2012141653/10A patent/RU2573909C2/ru not_active IP Right Cessation
- 2011-03-02 JP JP2012556223A patent/JP5840148B2/ja not_active Expired - Fee Related
-
2012
- 2012-08-28 CO CO12146129A patent/CO6592086A2/es unknown
- 2012-08-29 CL CL2012002378A patent/CL2012002378A1/es unknown
-
2015
- 2015-10-15 US US14/884,081 patent/US9611499B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013524775A5 (enExample) | ||
| RU2012141653A (ru) | Способ получения растворимого рекомбинантного белка интерферона без денатурирования | |
| Hu et al. | CXCL8 of Scophthalmus maximus: Expression, biological activity and immunoregulatory effect | |
| CN101892241B (zh) | 一种草鱼白细胞介素1β基因和蛋白及其重组表达方法 | |
| CN103570836B (zh) | 一种重组猪干扰素β1-Fc融合蛋白及其编码基因和表达方法 | |
| CN106479946B (zh) | 一种过表达结核分枝杆菌Rv3586的重组卡介苗菌株及其应用 | |
| CN103193887B (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
| Mohammadinezhad et al. | Efficient osmolyte-based procedure to increase expression level and solubility of infectious hematopoietic necrosis virus (IHNV) nucleoprotein in E. coli | |
| Behera et al. | Characterisation and expression analysis of trophozoite and cyst proteins of Acanthamoeba spp. isolated from Acanthamoeba keratitis (AK) patient | |
| CN103265637B (zh) | 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法 | |
| CN103232545B (zh) | 一种重组猪干扰素α1-Fc融合蛋白及其编码基因和表达方法 | |
| Xu et al. | Enhancement of recombinant human interleukin-22 production by fusing with human serum albumin and supplementing N-acetylcysteine in Pichia Pastoris | |
| WO2016004904A2 (zh) | 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法 | |
| CN104789625A (zh) | 人α防御素5在酿酒酵母中分泌表达的方法 | |
| CN105399808B (zh) | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 | |
| TW201629093A (zh) | 新穎美洲室塵蟎蛋白質 | |
| CN117659138B (zh) | 一种流感病毒np蛋白突变体及其应用 | |
| CN104561022B (zh) | 家猪肿瘤坏死因子突变体的构建及蛋白表达纯化方法 | |
| Puspasari et al. | Construction and expression of a synthetic gene encoding nonstructural glycoprotein NS1 of dengue 2 virus in Pichia pastoris | |
| CN116606366B (zh) | 一种石斑鱼白介素15及其制备方法和用途 | |
| CN103739684A (zh) | 黑灵芝真菌免疫调节蛋白的制备方法及其应用 | |
| CN103864916B (zh) | 人胸腺肽β4三倍体蛋白、编码基因及其分离纯化方法 | |
| Tsujimura et al. | Allergy vaccines using a mycobacterium-secreted antigen, Ag85B, and an IL-4 antagonist | |
| Starck et al. | Recombinant Production and Functional Characterization of Andes Virus Gn and Gc in Pichia pastoris: A Path Towards Subunit Vaccine Development | |
| US11339377B2 (en) | SO3 chromatography for use in a method for virus purification |